Symbolbild · KI-generiert
Vaxil Bio Ltd.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Vaxil Bio Ltd is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin successfully completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. The company aims to continue to develop ImMucin, a COVID19 and a tuberculosis vaccine/treatment that has demonstrated promising preliminary results with further preclinical evaluation planned. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.
Company description as published by the issuer via TMX Money.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Vaxil Bio Ltd. | VXL | TSXV | 497.016 USD |
| Element Lifestyle Retirement Inc. | ELM | TSXV | 502.419 USD |
| Imaging Dynamics Company Ltd. | IDL | TSXV | 552.540 USD |
| Jolt Health Inc. | JOLT.X | CSE | 417.390 USD |
| Waverley Pharma Inc. | WAVE | TSXV | 577.425 USD |
| Entheon Biomedical Corp. | ENBI.X | CSE | 592.777 USD |
| Mary Agrotechnologies Inc | MARY | CSE | 614.892 USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.